2359413-58-2

2359413-58-2 structure

2359413-58-2 structure

Name: Bapotulimab
Chemical Name: Bapotulimab
CAS Number: 2359413-58-2
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-01-11 21:50:25
Modify Date: 2024-01-15 12:51:45
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects[1].

Name	Bapotulimab

Description	Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	Bapotulimab 阻断 ILDR2 对 T 细胞活化的免疫抑制作用。Bapotulimab 具有小鼠/人交叉反应性，因为 ILDR2 在人和鼠直系同源物的细胞外结构域之间具有 98% 的序列同一性[1]。 Bapotulimab (BAY-1905254；5、25、100 或 500 ng/mL) 在体外促进 T 细胞活化并增强抗原特异性 T 细胞增殖[1]。
In Vivo	Bapotulimab（BAY-1905254；10 mg/kg；腹腔注射；在第 1 天和第 4 天）显示抗原特异性 T 细胞增殖和细胞毒性显着增加[1]。 Animal Model: 8- to 12-week-old CD45.1-expressing C57BL/6 wild-type mice injected with OT-I transgenic T cells[1] Dosage: 10 mg/kg Administration: i.p.; on days 1 and 4 Result: Showed significantly increased antigen-specific T-cell proliferation and cytotoxicity.
References	[1]. Julia Huetter, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911.

No Any Chemical & Physical Properties